

REMARKS

The present amendments are made to correct typographical errors in the specification. Favorable action on and early allowance of the claims are respectfully requested.

If the Examiner has any questions concerning this application, he or she is invited to contact Mr. Richard Gallagher, Reg. No., 28,781 at (703) 205-8008.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees, particularly extension of time fees, required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By _____

 28,781

Raymond C. Stewart
Reg. No. 21,066

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

RCS/RG/clb

MARKED UP VERSION OF AMENDMENTS

IN THE SPECIFICATION:

Page 13

Line 4, change "1-[4-[(1-hydroxyethyl)phenethyl]piperidin-4]" to --1-[4-(1-hydroxyethyl)phenethyl]piperidin-4--.

Page 14

Line 10, change "1-[3-[(2-hydroxyethoxy)phenethyl]piperidin-4]" to --1-[1-[2-hydroxyethoxy)phenethyl]piperidin-4--.

Page 17

Line 16, change '1-[1-(4-t-butoxycarbonyl)piperidin-4-yl]-6-' to --1-[1-(t-butoxycarbonyl)piperidin-4-yl]-6--.

line 18, change "1-[1-(4-t-butoxycarbonyl)piperidin-4-yl]-6-" to --1-[1-(t-butoxycarbonyl)piperidin-4-yl]-6--.

line 20, change "1-[1-(4-t-butoxycarbonyl)piperidin-4-yl]-6-" to --1-[1-(t-butoxycarbonyl)piperidin-4-yl]-6--.

Page 35

Line 8, change "hydroxypiperidin-1-ylcarbonylmethyl)indole," to --hydroxypiperidin-1-yl)carbonylmethylindole,--.

Page 36

Line 14, change "methoxypyridin-5-ylcarbonyl)indole," to

--methoxypyridin-5-yl)carbonylindole,--.

Page 39

Line 2, change "dioxolan-2-ylmethyl)carbamoylmethylindole," to --dioxolan-2-yl)methylcarbamoylmethylindole,--.

Page 56

Line 1, change "(4)" to --(5)--.

Page 194 (counting the formula as one line)

Line 22, change "1-(4-[(1" to --1-[1-4-(1---.

Page 213 (counting the formula as one line)

Line 16, change "1-[3-[(2-" to --1-[1-[3-(2---.

Page 274 (counting the formula as one line)

Line 4, change "1-[1-(4-t-" to --1-[1-(t---.

line 8, change "1-(4-t-" to --1-(t--.

Page 275 (counting the formula as one line)

Line 5, change "1-[1-(4-t-butoxycarbonyl)-" to --1-[1-(t-butoxycarbonyl)---.

line 9, change "1-[1-(4-t-" to --1-[1-(t--.

Page 276 (counting the formula as one line)

Line 11, change "1-[1-(4-t-" to --1-[1-(t---.

line 16, change "1-[1-(4-t-butoxycarbonyl)piperidin-4-yl]-6-" to --1-[1-(t-butoxycarbonyl)piperidin-4-yl]-6--.

Page 490

Line 10, delete "ethyl acetate" (second occurrence).

TOP SECRET INVESTIGATIVE INFORMATION

Page 491 (counting the formula as one line)

Line 2, change "7.04" to --7.04g--.

Page 537

Line 5, change "4-yl]-6-(4-hydroxypiperidin-1-ylcarbonylmethyl)indole" to
--4-yl]-6-(4-hydroxypiperidin-1-yl)carbonylmethylindole--.

Page 559

Line 13, change "4-yl]-6-(2-methoxypyridin-5-ylcarbonyl)indole" to --"4-
yl]-6-(2-methoxypyridin-5-yl)carbonylindole--.

Page 595

Line 24, change "4-yl]-6-(1,3-dioxolan-2-ylmethyl)carbamoyl
methylindole" to --"4-yl]-6-(1,3-dioxolan-2-yl)methylcarbamoylmethylindole--.

Page 598

Line 12, change "(ml) to --(100 ml)--.

DO NOT FILE UNTIL 12 MONTHS AFTER FILING WITH THE PATENT AND TRADEMARK OFFICE